Brain Tumor Biology

Group leader: Petra Hamerlik

Brain Tumor Biology

Glioblastoma (GBM) is the most prevalent and lethal primary brain tumor. Despite maximal therapeutic intervention, every GBM patient dies of their disease, making therapeutic resistance an urgent area of study.

The main goal of our research is to deepen the understanding of functional interplay between DNA repair mechanisms, cellular hierarchies and therapeutic resistance in GBM. We believe that the identification and successful targeting of mediators of these responses may disrupt resistance to cancer therapies and so fulfil their therapeutic promises.

Petra Hamerlik

Petra Hamerlik

Five selected publications:

Michaelsen R.M, et al., Hamerlik P. VEGF-C sustains VEGFR-2 activation under bevacizumab therapy and promotes glioblastoma maintenance. (2018) Neuro-Oncology.

Staberg M, et al., Hamerlik P. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B. (2018) Mol Oncol. [Epub ahead of print] PubMed PMID: 29360266.

Staberg M et al., Hamerlik P. Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. (2016) Cellular Oncology 40:21-32.

Rasmussen RD al, Hamerlik P. BRCA1-regulated RRM2 expression protects GBM cells from endogenous replication stress and promotes tumorigenecity. (2016) Nature Communications 7:13398

Rasmussen RD, Gajjar MK, Jensen KE, Hamerlik P. Synergistic inhibition of GBM cell survival by co-targeting HDAC and PARP. (2016) Molecular Oncology 10(5):751-63

ORCID:

Petra Hamerlik

0000-0002-5856-0161